Does PALBOCICLIB Cause Interstitial lung disease? 282 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 282 reports of Interstitial lung disease have been filed in association with PALBOCICLIB (Ibrance). This represents 0.3% of all adverse event reports for PALBOCICLIB.
282
Reports of Interstitial lung disease with PALBOCICLIB
0.3%
of all PALBOCICLIB reports
55
Deaths
134
Hospitalizations
How Dangerous Is Interstitial lung disease From PALBOCICLIB?
Of the 282 reports, 55 (19.5%) resulted in death, 134 (47.5%) required hospitalization, and 17 (6.0%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for PALBOCICLIB.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which PALBOCICLIB Alternatives Have Lower Interstitial lung disease Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID